/CING
CING Stock - Cingulate Inc.
Healthcare|BiotechnologyNASDAQ
$3.97+2.85%
+$0.11 (+2.85%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.55
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+177.1%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CING
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.93 – $4.01
TARGET (TP)$11.00
STOP LOSS$3.65
RISK/REWARD1:22.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.75
52W High$6.01
52W Low$3.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-653,090 | $-582,918 | $-621,993 | $-808,441 | $-842,353 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-15,644,973 | $-22,759,190 | $-17,501,718 | $-20,679,398 | $-7,083,363 |
| Net Income | $-15,545,737 | $-23,534,947 | $-17,676,232 | $-20,740,493 | $-7,183,615 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-10.20 | $-311.99 | $-31.20 | $-55.80 | $-12.70 |
Company Overview
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
50%
Hold / Neutral
1
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
1 Bullish1 Neutral/Bearish
Price Targets
$12
Average Target
↑ 202.3% Upside
Now
$12
Low
$12
Average
$12
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 10th 2025 | ROTH MKM | Initiation | Buy | $12 |
| December 22nd 2023 | Laidlaw | Downgrade | Hold | - |
Earnings History & Surprises
CINGBeat Rate
31%
Last 16 quarters
Avg Surprise
-7682.6%
EPS vs Estimate
Beats / Misses
5/11
Last 12 quarters
Latest EPS
$-1.35
Q4 2025
EPS Surprise History
Q1 24
-57.6%
$-7.66vs$-4.86
Q2 24
+72.7%
$-7.20vs$-26.41
Q3 24
+3.0%
$-5.47vs$-5.64
Q4 24
+17.6%
$-1.83vs$-2.22
Q1 25
+90.5%
$-0.14vs$-1.48
Q2 25
-4.0%
$-1.04vs$-1.00
Q3 25
-32.9%
$-1.09vs$-0.82
Q4 25
-68.8%
$-1.35vs$-0.80
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.52 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.80 | $-1.35 | -68.8% | ✗ MISS |
Q3 2025 | Aug 19, 2025 | $-0.82 | $-1.09 | -32.9% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-1.00 | $-1.04 | -4.0% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-1.48 | $-0.14 | +90.5% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-2.22 | $-1.83 | +17.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-5.64 | $-5.47 | +3.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-26.41 | $-7.20 | +72.7% | ✓ BEAT |
Q1 2024 | Mar 29, 2024 | $-4.86 | $-7.66 | -57.6% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-57.62 | $-72.03 | -25.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.35 | $-136.85 | -39000.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-64.83 | $-84.03 | -29.6% | ✗ MISS |
Q1 2023 | Mar 10, 2023 | $-86.43 | $-98.44 | -13.9% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.37 | $-86.43 | -23259.5% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.58 | $-86.43 | -14801.7% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.23 | $-105.64 | -45830.4% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.39 | $-0.32 | +17.9% | ✓ BEAT |
Q4 2021 | Dec 9, 2021 | — | $-30.40 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-324.48 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-28.31 | — | — |
Latest News
Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Executive Chairman Of The Board But Will Continue To Serve As Chairman
➖ NeutralBenzinga•Dec 15, 2025, 02:21 PM
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58
📈 PositiveBenzinga•Dec 8, 2025, 10:19 AM
Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16
➖ NeutralBenzinga•Nov 19, 2025, 06:00 PM•Also:
Cingulate Releases Phase 3 Trial Results For Its ADHD Treatment CTX-1301 Showing The Drug Met Its Primary Endpoints, Showing Dose-Dependent Improvements On ADHD Symptom And Severity Scales, And Demonstrated Effective Once-Daily Symptom Relief Using The Company's Precision Timed Release Technology
📈 PositiveBenzinga•Oct 28, 2025, 12:04 PM
Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual Meeting In Chicago
📈 PositiveBenzinga•Oct 23, 2025, 08:48 PM
Roth Capital Maintains Buy on Cingulate, Raises Price Target to $17
📈 PositiveBenzinga•Oct 15, 2025, 05:49 PM
Cingulate Announces That U.S. FDA Accepts For Review Its New Drug Application For CTx-1301, Its Lead ADHD Treatment Candidate For Children And Adults
📈 PositiveBenzinga•Oct 14, 2025, 12:02 PM
Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, Its Lead Drug Candidate For Treating ADHD
📈 PositiveBenzinga•Sep 17, 2025, 12:55 PM
Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $62
📈 PositiveBenzinga•Aug 22, 2025, 09:54 AM
Cingulate Posts Wider Loss in Q2
📉 NegativeThe Motley Fool•Aug 19, 2025, 05:58 PM
Cingulate Q2 EPS $(1.09) Misses $(0.84) Estimate
📉 NegativeBenzinga•Aug 19, 2025, 01:46 PM
Frequently Asked Questions about CING
What is CING's current stock price?
Cingulate Inc. (CING) is currently trading at $3.97 per share. The stock has moved +2.85% today.
What is the analyst price target for CING?
The average analyst price target for CING is $11.00, based on 1 analyst.
What sector is Cingulate Inc. in?
Cingulate Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CING's market cap?
Cingulate Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does CING pay dividends?
No, Cingulate Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLR
Allarity Therapeutics, Inc.
$1.03
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CASI
CASI Pharmaceuticals, Inc.
$0.81
Mkt Cap: $0.0B
CLSD
Clearside Biomedical, Inc.
$1.00
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
KAPA
Kairos Pharma, Ltd.
$0.86
Mkt Cap: $0.0B
LEXX
Lexaria Bioscience Corp.
$0.58
Mkt Cap: $0.0B
LIXT
Lixte Biotechnology Holdings, Inc.
$4.32
Mkt Cap: $0.0B
NCNA
NuCana plc
$3.56
Mkt Cap: $0.0B
SYBX
Synlogic, Inc.
$1.20
Mkt Cap: $0.0B
Explore stocks similar to CING for comparison